Ipratropium — $0 with Membership
Ipratropium has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Ipratropium Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $89.99 |
Free with membership subject to the listed formulary limits.
About Ipratropium
Ipratropium is a prescription medication. Ask your doctor if Ipratropium is right for you.
Other strengths and forms of Ipratropium
- Ipratropium Nasal
- Ipratropium Bromide
- Ipratropium 17 mcg inhaler
- Ipratropium Bromide 0.0 6% 15mL 0.06% (42mcg/Spray ) Nasal Spray
Combination products containing Ipratropium
Conditions Treated with Ipratropium
How to Check Ipratropium Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Ipratropium at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Asthma / Acute Bronchospasm
Also listed for COPD
Other medications in Respiratory
About Ipratropium
Ipratropium is a vital medication often prescribed to help people with chronic obstructive pulmonary disease (COPD) breathe more easily. As a short-acting bronchodilator, it offers quick relief for respiratory symptoms. TheDrugClub members can access this important medication with a $0 co-pay and free home delivery, making managing your health more affordable.
Ipratropium is primarily used to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It helps open up the airways in your lungs, making it easier to breathe. While less common, it can also be used as an add-on treatment for asthma in some cases, particularly for those who don't respond well to other common asthma medications or who experience bronchospasm from beta-blockers. It's often prescribed as an inhaler (metered-dose inhaler or nebulizer solution) for direct delivery to the lungs, providing relief from symptoms like wheezing, shortness of breath, and chest tightness.
This medication belongs to a class of drugs called anticholinergics. It works by blocking the action of acetylcholine, a natural substance in the body that can cause the muscles around the airways to constrict. By blocking these receptors in the lungs
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Ipratropium is approved for (FDA label)
Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Source: Read the full FDA label on DailyMed. Label effective date: July 24, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Ipratropium (FDA label)
Adverse reaction information concerning ipratropium bromide inhalation solution is derived from 12-week active-controlled clinical trials. Additional information is derived from foreign post-marketing experience and the published literature. All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials appear in the table below. Additional adverse reactions reported in less than three percent of the patients treated with ipratropium bromide include tachycardia, palpitations, eye pain, urinary retention, urinary tract infection and urticaria. Cases of precipitation or worsening of narrow-angle glaucoma, mydriasis, and acute eye pain have been reported. Lower respiratory adverse reactions (bronchitis, dyspnea and bronchospasm) were the most common events leading to discontinuation of ipratropium bromide therapy in the 12-week trials.
Source: FDA prescribing information (DailyMed). Set ID: 6b730dd7-4d93-403a-bfd2-fa0efa298b75. Label effective date: July 24, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Ipratropium (FDA label)
Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.
Source: FDA prescribing information (DailyMed). Set ID: 6b730dd7-4d93-403a-bfd2-fa0efa298b75. Label effective date: July 24, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Ipratropium (FDA label)
Ipratropium bromide has been shown to be a safe and effective bronchodilator when used in conjunction with beta adrenergic bronchodilators. Ipratropium bromide has also been used with other pulmonary medications, including methylxanthines and corticosteroids, without adverse drug interactions.
Source: FDA prescribing information (DailyMed). Set ID: 6b730dd7-4d93-403a-bfd2-fa0efa298b75. Label effective date: July 24, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.